Strata Critical Medical (NASDAQ:SRTA) Announces Earnings Results

Strata Critical Medical (NASDAQ:SRTA) released its quarterly earnings data on Tuesday. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.10), FiscalAI reports. The business had revenue of $74.08 million during the quarter. Strata Critical Medical had a negative return on equity of 2.97% and a net margin of 15.71%.

Here are the key takeaways from Strata Critical Medical’s conference call:

• Q3 results exceeded guidance, with revenue up 50.3% year over year to $74.1 million, adjusted EBITDA rising to $9.6 million, and record free cash flow of $8.6 million. Management reiterated 2026 revenue, adjusted EBITDA, and free-cash-flow guidance.
• The clinical segment grew 20.3% sequentially and more than 30% on a comparable year-over-year basis, even as industry transplant volumes declined seasonally. Management attributed the performance to market-share gains from its integrated organ recovery, perfusion, and logistics offering, with clinical growth expected to lead in 2027.
• Logistics revenue declined 6.9% sequentially and 3.5% year over year, pressured by seasonal transplant weakness and approximately 10% shorter industry trip distances, particularly following changes to lung-allocation rules. The company expects logistics revenue to be roughly flat sequentially in Q4, while clinical drives overall growth.
• Strata ended the quarter with $41.6 million in cash and short-term investments after receiving $15.3 million from its Passenger earnout, with another $27.5 million potentially due in early 2027. The company authorized a $20 million share repurchase while maintaining plans to accelerate acquisitions at targeted mid-single-digit valuation multiples.

Strata Critical Medical Trading Up 6.9%

SRTA traded up $0.29 during midday trading on Tuesday, reaching $4.58. The company’s stock had a trading volume of 479,997 shares, compared to its average volume of 949,200. The firm has a market capitalization of $404.74 million, a price-to-earnings ratio of -115.13 and a beta of 2.43. Strata Critical Medical has a 1 year low of $3.95 and a 1 year high of $6.50. The stock’s 50-day moving average is $5.07 and its 200-day moving average is $5.21.

Insider Buying and Selling at Strata Critical Medical

In other news, Director Reginald Love sold 5,091 shares of Strata Critical Medical stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $5.75, for a total transaction of $29,273.25. Following the completion of the transaction, the director directly owned 146,481 shares in the company, valued at approximately $842,265.75. This trade represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 15.50% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Strata Critical Medical from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Strata Critical Medical Company Profile

Blade Air Mobility, Inc provides air transportation alternatives to the congested ground routes in the United States. It provides its services through charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes. The company was founded in 2014 and is headquartered in New York, New York.